Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)
NCT ID: NCT02707042
Last Updated: 2025-09-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
108 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-03-22
Study Completion Date
2025-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
More than 250 million courses of antibiotics are prescribed annually in the ambulatory care setting in the United States alone, including more than 40 million in children under 18 years of age. The perception that antibiotic use has minimal attendant adverse side effects contributes to the over-utilization of antibiotics in clinical circumstances when they are not strictly indicated. We have learned much about the human microbiome. The emerging view is of profound life-long bi-directional interactions between our microbiota and our cells. Perturbations in the microbiota affect metabolic, immune, and cognitive physiology in experimental animal models. When a person takes an antibiotic, the antibiotic diffuses via the blood into all body compartments, selecting for resistance. We propose to examine the effects of two commonly used antibiotics (the beta-lactam, amoxicillin and the macrolide azithromycin) on human microbial populations and on metabolic and immune physiology, studying healthy human volunteers in a randomized controlled clinical trial at the NIH Clinical Center. Our hypothesis is that in addition to acutely perturbing the human microbiome, these agents will have measurable metabolic and immunologic effects, with residual effects in the weeks that follow. To test this hypothesis, we will assess the effects of a brief therapeutic course of antibiotics on microbiome and metagenome composition. After an initial evaluation period, antibiotics will be given for 7 days or 5 days (depending on the antibiotic), and there will be a post-treatment evaluation. A control group will receive no drug intervention. Specimens will be obtained from multiple sites at each of 10 time points occurring before, during, and after antibiotic administration, and used for estimating bacterial and fungal composition and gene content. We will also assess the effects of the antibiotic course on markers of innate and adaptive immunity as well as markers of metabolic and hormonal physiology. A subgroup of subjects will be studied in the clinical center metabolic chamber to assess 24-hour energy expenditure and its components (sleeping, diet-induced, and activity energy expenditure), as well as macronutrient oxidation rates (carbohydrate, fat, and protein), during 3 of the 10 study visits. In addition to the primary data analyses, we will build a model that integrates the temporal data to begin to understand the complex intertwined physiology between microbiome and host.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children
NCT02935374
Acute Otitis Media
COMPLETED
PHASE4
Effect of Minocycline & Amoxicillin on Antibiotic Resistant Bacteria and Indigenous Microbiotas
NCT02030912
Antibiotic Resistant Bacteria
COMPLETED
PHASE4
Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
NCT03672630
Mycobacterium Avium Complex
Nontuberculous Mycobacterium Infection
COMPLETED
PHASE2/PHASE3
Evaluate Pathogens and Immunity to Acute Otitis Media in Healthy Children.
NCT02591563
Nasopharyngeal Colonization and Acute Otitis Media
ACTIVE_NOT_RECRUITING
Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease
NCT00325897
Pulmonary Disease, Chronic Obstructive
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
More than 250 million courses of antibiotics are prescribed annually in the ambulatory care setting in the United States alone, including more than 40 million in children under 18 years of age. The perception that antibiotic use has minimal attendant adverse side effects contributes to the over-utilization of antibiotics in clinical circumstances when they are not strictly indicated. We have learned much about the human microbiome. The emerging view is of profound life-long bi-directional interactions between our microbiota and our cells. Perturbations in the microbiota affect metabolic, immune, and cognitive physiology in experimental animal models. When a person takes an antibiotic, the antibiotic diffuses via the blood into all body compartments, selecting for resistance. We propose to examine the effects of two commonly used antibiotics (the beta-lactam, amoxicillin and the macrolide azithromycin) on human microbial populations and on metabolic and immune physiology, studying healthy human volunteers in a randomized controlled clinical trial at the NIH Clinical Center. Our hypothesis is that in addition to acutely perturbing the human microbiome, these agents will have measurable metabolic and immunologic effects, with residual effects in the weeks that follow. To test this hypothesis, we will assess the effects of a brief therapeutic course of antibiotics on microbiome and metagenome composition. After an initial evaluation period, antibiotics will be given for 7 days or 5 days (depending on the antibiotic), and there will be a post-treatment evaluation. A control group will receive no drug intervention. Specimens will be obtained from multiple sites at each of 10 time points occurring before, during, and after antibiotic administration, and used for estimating bacterial and fungal composition and gene content. We will also assess the effects of the antibiotic course on markers of innate and adaptive immunity as well as markers of metabolic and hormonal physiology. A subgroup of subjects will be studied in the Clinical Center metabolic chamber to assess 24-hour energy expenditure and its components (sleeping, diet-induced, and activity energy expenditure), as well as macronutrient oxidation rates (carbohydrate, fat, and protein), during 3 of the 10 study visits. In addition to the primary data analyses, we will build a model that integrates the temporal data to begin to understand the complex intertwined physiology between microbiome and host.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Normal Physiology
Healthy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Control
Group Type
OTHER
Control
Intervention Type
OTHER
A group of volunteers will receive no antibiotics and will serve as study controls.
Group B
Amoxicillin
Group Type
OTHER
Amoxicillin
Intervention Type
DRUG
7-day therapeutic oral course of twice daily amoxicillin
Group C
Azithromycin
Group Type
OTHER
Azithromycin
Intervention Type
DRUG
5-day oral course of once-daily azithromycin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amoxicillin
7-day therapeutic oral course of twice daily amoxicillin
Intervention Type
DRUG
Azithromycin
5-day oral course of once-daily azithromycin
Intervention Type
DRUG
Control
A group of volunteers will receive no antibiotics and will serve as study controls.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Healthy women and men will be eligible for study participation if they meet the following criteria:
* A participant will have passed his/her 18th birthday and will not have attained the age of 50 at the time of enrollment.
* Willing to allow storage of their biological samples.
* Able to comply with study procedures and swallow capsules.
* A participant will have passed his/her 18th birthday and will not have attained the age of 50 at the time of enrollment.
* Willing to allow storage of their biological samples.
* Able to comply with study procedures and swallow capsules.
Exclusion Criteria
An individual who meets any of the following criteria will be excluded from study participation:
* Body Mass Index (BMI) greater than or equal to 35 or less than or equal to 18 kg/M(2).
* Vital signs outside of acceptable range at Screening Visit, i.e., blood pressure \>160/100, oral temperature \>100 degrees F, pulse \>100.
* Use of any of the following drugs or devices within the last 6 months:
* systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral);
* oral, intravenous, intramuscular, nasal, or inhaled corticosteroids;
* cytokines;
* methotrexate or immunosuppressive cytotoxic agents;
* large doses of commercial probiotics consumed (greater than or equal to 10(8) cfu or organisms per day), including tablets, capsules, lozenges, chewing gum, or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, and foods do not apply.
* anabolic steroids;
* intrauterine device, combination hormone vaginal ring for contraception (due to unknown duration of local hormone effects), topical or systemic estrogens. Oral contraceptives with a standard 28-day cycle will be permitted if the subject has been consistently taking them for at least 1 month;
* oral, topical, intramuscular testosterone preparations.
* Illicit drug use, including amphetamines, cocaine, or heroin, within the last 6 months. Marijuana use is not exclusionary.
* Chronic smokers and subjects who use smokeless tobacco products (due to known effects of tobacco on the oral microbiome).
* Claustrophobia.
* Use of antacids (proton pump inhibitors, sucralfate, H1 and H2 antagonists, and those containing aluminum magnesium) within the last 3 months.
* Use of laxatives or enemas within the last 3 months.
* Diagnostic colonoscopy within the last 6 months.
* Use of topical antibiotics or topical steroids on the face, scalp, or neck, or on arms, forearms, or hands within the previous 30 days.
* Use of vaginal/vulvar medications, including antifungals, within the previous 30 days. Subjects may continue to use permitted vaginal contraceptives (spermicides and female condoms) until 24 hours prior to sampling
* Use of isotretinoin within the past 5 years.
* Intranasal influenza vaccination within the last 6 months due to effects on mucosal immunity.
* Acute disease at the time of enrollment (defer enrollment until subject recovers). Acute disease is defined as the presence of a moderate or severe illness with or without fever.
* Chronic, clinically significant (unresolved, requiring ongoing medical management or medication) pulmonary, cardiovascular, dermatologic, endocrine, GI, hepatic, or renal functional abnormality, as determined by medical history, physical examination, and/or laboratory testing. Includes, but not limited to:
* A history of diabetes mellitus (Type 1 or 2), pituitary disease, hypothyroidism, hyperthyroidism
* A history of physician-diagnosed asthma
* A history of allergy to any antibiotic medications, including amoxicillin (penicillin) and/or azithromycin (macrolide)
* A history of food allergy requiring dietary accommodation
* Lactose-intolerance requiring dietary accommodation
* A history of a bleeding disorder
* Mononucleosis
* Liver disease, including non-alcoholic fatty liver disease, AST or ALT \> 1.5 times normal value, cirrhosis
* Renal disease, as defined by serum creatinine concentrations \> 1.5 mg/dL and/or overt proteinuria
* Central nervous system disease, including previous history of cerebrovascular accidents, dementia, and neurodegenerative disorders
* Clinically significant abnormal results on electrocardiogram (ECG) that in the opinion of the PI, would place the patient at increased risk of QT-prolongation or other cardiac event
* Genitourinary/Gynecologic conditions, including:
* Treatment for or suspicion of ever having had toxic shock syndrome
* History of hysterectomy or oophorectomy
* History of condyloma or human papillomavirus diagnosed within the previous 2 years
* History of candidiasis, urinary tract infection, or sexually transmitted disease (specifically chlamydia, gonorrhea, syphilis, genital herpes, trichomoniasis) diagnosed within the previous 6 months
* Evidence (by history or physical exam) of vulvar or vaginal irritation at screening
* History of vulvar, vaginal, or cervical dysplasia within the previous 5 years
* History of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.
* Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
* Recent history of excessive alcohol consumption defined as more than five 1.5-ounce servings of 80-proof distilled spirits, five 12-ounce servings of beer, or five 5-ounce servings of wine at one sitting over the last 30 days.
* Positive test for HIV, hepatitis B virus, or hepatitis C virus indicating infection (hepatitis B seropositivity conferred by vaccination is not exclusionary).
* Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired).
* Major surgery of the GI tract, including cholecystectomy or appendectomy, in the past 5 years. Any major bowel resection at any time.
* History of gastric stapling, lap band, or surgical procedure for treatment of obesity.
* History of GI disorders or diseases including:
* inflammatory bowel disease (IBD) including ulcerative colitis, Crohn s disease (of any severity), or indeterminate colitis;
* irritable bowel syndrome (IBS);
* persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent), gastric or duodenal ulcer;
* Celiac disease;
* chronic constipation.
* Active behavioral or psychiatric conditions that would be incompatible with a safe and successful participation in the study, including major depression, anxiety disorder, schizophrenia, and presence of psychotic symptoms.
* Active eating disorders, including anorexia nervosa, bulimia, or binge eating syndrome.
* Use of weight-loss drugs within the past 5 years.
* Weight change (intended or unintended; loss or gain) of more than 10% of total body weight in the 3 months before admission.
* Regular urinary incontinence necessitating use of incontinence protection garments.
* Female who is pregnant, intending to become pregnant, or lactating.
* History of recurrent rashes within the past 6 months.
* At the time of the screening visit:
* multiple blisters, pustules, boils, abscesses, erosions or ulcers on the scalp, face, neck, arms, forearms, or hands;
* uniformly thickened, cracking, dry skin on bilateral palms and/or soles;
* disseminated rash (at multiple body sites or extending throughout a broad body area).
* Subjects who are unable to complete required study visits per allotted visit windows.
* Any condition that, in the opinion of the investigator, contraindicates participation in this study.
* Body Mass Index (BMI) greater than or equal to 35 or less than or equal to 18 kg/M(2).
* Vital signs outside of acceptable range at Screening Visit, i.e., blood pressure \>160/100, oral temperature \>100 degrees F, pulse \>100.
* Use of any of the following drugs or devices within the last 6 months:
* systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral);
* oral, intravenous, intramuscular, nasal, or inhaled corticosteroids;
* cytokines;
* methotrexate or immunosuppressive cytotoxic agents;
* large doses of commercial probiotics consumed (greater than or equal to 10(8) cfu or organisms per day), including tablets, capsules, lozenges, chewing gum, or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, and foods do not apply.
* anabolic steroids;
* intrauterine device, combination hormone vaginal ring for contraception (due to unknown duration of local hormone effects), topical or systemic estrogens. Oral contraceptives with a standard 28-day cycle will be permitted if the subject has been consistently taking them for at least 1 month;
* oral, topical, intramuscular testosterone preparations.
* Illicit drug use, including amphetamines, cocaine, or heroin, within the last 6 months. Marijuana use is not exclusionary.
* Chronic smokers and subjects who use smokeless tobacco products (due to known effects of tobacco on the oral microbiome).
* Claustrophobia.
* Use of antacids (proton pump inhibitors, sucralfate, H1 and H2 antagonists, and those containing aluminum magnesium) within the last 3 months.
* Use of laxatives or enemas within the last 3 months.
* Diagnostic colonoscopy within the last 6 months.
* Use of topical antibiotics or topical steroids on the face, scalp, or neck, or on arms, forearms, or hands within the previous 30 days.
* Use of vaginal/vulvar medications, including antifungals, within the previous 30 days. Subjects may continue to use permitted vaginal contraceptives (spermicides and female condoms) until 24 hours prior to sampling
* Use of isotretinoin within the past 5 years.
* Intranasal influenza vaccination within the last 6 months due to effects on mucosal immunity.
* Acute disease at the time of enrollment (defer enrollment until subject recovers). Acute disease is defined as the presence of a moderate or severe illness with or without fever.
* Chronic, clinically significant (unresolved, requiring ongoing medical management or medication) pulmonary, cardiovascular, dermatologic, endocrine, GI, hepatic, or renal functional abnormality, as determined by medical history, physical examination, and/or laboratory testing. Includes, but not limited to:
* A history of diabetes mellitus (Type 1 or 2), pituitary disease, hypothyroidism, hyperthyroidism
* A history of physician-diagnosed asthma
* A history of allergy to any antibiotic medications, including amoxicillin (penicillin) and/or azithromycin (macrolide)
* A history of food allergy requiring dietary accommodation
* Lactose-intolerance requiring dietary accommodation
* A history of a bleeding disorder
* Mononucleosis
* Liver disease, including non-alcoholic fatty liver disease, AST or ALT \> 1.5 times normal value, cirrhosis
* Renal disease, as defined by serum creatinine concentrations \> 1.5 mg/dL and/or overt proteinuria
* Central nervous system disease, including previous history of cerebrovascular accidents, dementia, and neurodegenerative disorders
* Clinically significant abnormal results on electrocardiogram (ECG) that in the opinion of the PI, would place the patient at increased risk of QT-prolongation or other cardiac event
* Genitourinary/Gynecologic conditions, including:
* Treatment for or suspicion of ever having had toxic shock syndrome
* History of hysterectomy or oophorectomy
* History of condyloma or human papillomavirus diagnosed within the previous 2 years
* History of candidiasis, urinary tract infection, or sexually transmitted disease (specifically chlamydia, gonorrhea, syphilis, genital herpes, trichomoniasis) diagnosed within the previous 6 months
* Evidence (by history or physical exam) of vulvar or vaginal irritation at screening
* History of vulvar, vaginal, or cervical dysplasia within the previous 5 years
* History of cancer except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.
* Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
* Recent history of excessive alcohol consumption defined as more than five 1.5-ounce servings of 80-proof distilled spirits, five 12-ounce servings of beer, or five 5-ounce servings of wine at one sitting over the last 30 days.
* Positive test for HIV, hepatitis B virus, or hepatitis C virus indicating infection (hepatitis B seropositivity conferred by vaccination is not exclusionary).
* Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired).
* Major surgery of the GI tract, including cholecystectomy or appendectomy, in the past 5 years. Any major bowel resection at any time.
* History of gastric stapling, lap band, or surgical procedure for treatment of obesity.
* History of GI disorders or diseases including:
* inflammatory bowel disease (IBD) including ulcerative colitis, Crohn s disease (of any severity), or indeterminate colitis;
* irritable bowel syndrome (IBS);
* persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent), gastric or duodenal ulcer;
* Celiac disease;
* chronic constipation.
* Active behavioral or psychiatric conditions that would be incompatible with a safe and successful participation in the study, including major depression, anxiety disorder, schizophrenia, and presence of psychotic symptoms.
* Active eating disorders, including anorexia nervosa, bulimia, or binge eating syndrome.
* Use of weight-loss drugs within the past 5 years.
* Weight change (intended or unintended; loss or gain) of more than 10% of total body weight in the 3 months before admission.
* Regular urinary incontinence necessitating use of incontinence protection garments.
* Female who is pregnant, intending to become pregnant, or lactating.
* History of recurrent rashes within the past 6 months.
* At the time of the screening visit:
* multiple blisters, pustules, boils, abscesses, erosions or ulcers on the scalp, face, neck, arms, forearms, or hands;
* uniformly thickened, cracking, dry skin on bilateral palms and/or soles;
* disseminated rash (at multiple body sites or extending throughout a broad body area).
* Subjects who are unable to complete required study visits per allotted visit windows.
* Any condition that, in the opinion of the investigator, contraindicates participation in this study.
Minimum Eligible Age
18 Years
Maximum Eligible Age
49 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christa S Zerbe, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000. Emerg Infect Dis. 2003 Apr;9(4):432-7. doi: 10.3201/eid0904.020268.
Reference Type
BACKGROUND
McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 1995 Jan 18;273(3):214-9.
Reference Type
BACKGROUND
Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA. 2009 Aug 19;302(7):758-66. doi: 10.1001/jama.2009.1163.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2016-I-0078.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-I-0078
Identifier Type: -
Identifier Source: secondary_id
160078
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Selection of Antibiotic Resistance by Azithromycin and Clarithromycin in the Oral Flora
NCT00354952
COMPLETED
NA
Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children
NCT00539149
COMPLETED
PHASE4
N-of-1 Trials of Interventions to Improve Decision-making for Antibiotic Use
NCT05451836
COMPLETED
NA
Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians
NCT01099943
COMPLETED
NA
Amoxicillin Clavulanate in Treatment of Acute Otitis Media
NCT00299455
UNKNOWN
PHASE4
Outcome of Patients After a Negative Oral Challenge to Amoxicillin
NCT04922034
COMPLETED
Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate
NCT02340000
COMPLETED
PHASE4
Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry
NCT01244581
COMPLETED
PHASE3
Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
NCT01511107
TERMINATED
PHASE2
Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach
NCT00002682
COMPLETED
PHASE2
A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis
NCT00649831
COMPLETED
PHASE3
Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media
NCT00189098
COMPLETED
NA
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
NCT01435525
COMPLETED
Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens
NCT04946084
ACTIVE_NOT_RECRUITING
NA
Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis
NCT00245440
TERMINATED
PHASE4
The Microbiome Variability and Antibiotic Resistance of Chronic Suppurative Otitis
NCT03456739
UNKNOWN
Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort
NCT02286635
COMPLETED
PHASE1
Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial
NCT00250900
COMPLETED
NA
A Trial of Placebo Versus Macrolide for Mycoplasma Pneumoniae Childhood Pneumonia: MYTHIC Study
NCT06325293
RECRUITING
NA
An Open Label Trial of Azithromycin in Chronic Productive Cough
NCT02196493
UNKNOWN
PHASE3
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
NCT06246396
RECRUITING
PHASE4
The Optimization of Mycoplasm Pneumonia Antibiotic Therapy
NCT01259141
COMPLETED
NA
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
NCT03450187
COMPLETED
PHASE1
Dose Ranging Study of OTO-201 in AOMT
NCT02719158
COMPLETED
PHASE2